Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2023-10-02 Regulatory Filings
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is a formal announcement disseminated via RNS (RNS Number: 4025O) from Syncona Limited, dated October 2, 2023. The core content explicitly states the 'Total Voting Rights' as of September 30, 2023, referencing DTR 5.6.1 (Disclosure and Transparency Rules). This type of filing, which reports the total number of shares in issue and the total voting rights, is a specific regulatory disclosure related to share capital structure and shareholder notification thresholds. While it relates to share capital, it is not a general share issue announcement (SHA) or a transaction in own shares (POS). It is a mandatory disclosure regarding voting rights denominator. Since there is no specific code for 'Total Voting Rights Announcement', and it is a mandatory regulatory disclosure provided through the RNS system, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for specific regulatory disclosures not covered elsewhere. The document length is short (2763 chars), but it is the primary content, not an announcement of another report.
2023-10-02 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states 'Transaction in Own Shares' in the title section and details the purchase of 110,000 ordinary shares by the company as part of a 'share buyback programme'. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS), which covers company buying back or selling its own shares (share repurchase/issuance). The document is a specific regulatory filing detailing this transaction, not just an announcement of a report.
2023-10-02 English
Share Buyback Programme
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service), indicated by the 'RNS Number' and the closing statement referencing RNS as the Primary Information Provider. The core subject is the 'Share Buyback Programme' and the engagement of a broker (Numis Securities Limited) to conduct it. A share buyback or repurchase program falls directly under the category of a company buying back or selling its own shares. This aligns precisely with the definition for 'Transaction in Own Shares' (POS). Although it is an RNS announcement, the specific nature of the transaction (share repurchase) makes POS a more precise classification than the general RNS fallback.
2023-09-29 English
Launch of share buyback programme
Transaction in Own Shares Classification · 98% confidence The document is a formal announcement released via RNS (RNS Number: 0851O) from Syncona Limited, dated September 29, 2023. The core subject is the 'Launch of share buyback programme' of up to £40.0 million. A share buyback or repurchase program is explicitly defined under the 'Transaction in Own Shares' category (Code: POS). Although it involves capital allocation, the primary action described is the transaction involving the company's own shares, making POS the most specific fit over CAP (Capital/Financing Update). The document is not a short announcement linking to a report, but the report/announcement itself.
2023-09-29 English
Update on Gyroscope
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 9353L' and contains standard regulatory boilerplate language at the end, including references to 'RNS, the news service of the London Stock Exchange' and the 'Financial Conduct Authority'. The content is a brief update regarding the discontinuation of a drug development program (GT005) by Novartis, which impacts Syncona's expected milestone payments, resulting in a write-off. This is a time-sensitive, material announcement released via the RNS system, but it is not a full financial report (like 10-K or IR), a formal earnings release (ER), or a proxy statement. Since it is a general regulatory announcement disseminated through the London Stock Exchange's news service (RNS) that doesn't fit a more specific category like DIV, DIRS, or MANG, the most appropriate classification is the general regulatory filing category.
2023-09-11 English
Freeline reports Q2 2023 Financial Results
Earnings Release Classification · 98% confidence The document is an RNS announcement (RNS Number : 3729J) issued by Syncona Limited, reporting on the Q2 2023 Financial Results and Business Highlights of its portfolio company, Freeline Therapeutics Holdings plc. The text contains key financial metrics (cash position, R&D expenses, net loss) for the six months ended June 30, 2023, and includes condensed consolidated statements of operations. This content structure—a summary announcement of period-specific financial performance, including key figures and operational updates—is characteristic of an Earnings Release (ER). Although it contains financial data, it is presented as a press release summary, not the comprehensive filing itself (like a 10-Q or 10-K). Since it is an initial announcement of periodical financial results, ER is the most appropriate code. It is not an Interim Report (IR) because it is presented as a press release summary, not the full, detailed quarterly report. H1 2023
2023-08-15 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.